Recombinant Human Noggin Fc Chimera GMP Protein, CF GMP

R&D Systems, part of Bio-Techne | Catalog # 3344-GMP

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
3344-GMP-01M
3344-GMP-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

Q13253.1

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all Noggin Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human Noggin protein
 
Human Noggin
(Gln28-Cys232)
Accession # Q13253.1		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Manufactured and tested under cGMP guidelines.

Purity

>90%, by SDS-PAGE with silver staining, under reducing conditions.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Amino acid sequencing was blocked, suggesting it is consistent with Gln28 as the first N-terminal amino acid. Predicted N-terminal sequence: Gln28-His-Tyr-Leu-His-Ile-Arg-Pro-Ala-Pro

Predicted Molecular Mass

49.6 kDa (monomer)

SDS-PAGE

58-62 kDa, reducing conditions
110-130 kDa, non-reducing conditions

Activity

Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells.
The ED50 for this effect is 0.1-0.4 μg/mL in the presence of 30 ng/mL of Recombinant Human BMP‑4 (Catalog # 314-BP).

Host Cell Protein

< 5.0 ng per µg of protein when tested by ELISA.

Mycoplasma

Negative for Mycoplasma.

Scientific Data Images for Recombinant Human Noggin Fc Chimera GMP Protein, CF

Recombinant Human Noggin Fc Chimera GMP Protein Bioactivity

Recombinant Human Noggin Fc Chimera GMP Protein Bioactivity

GMP-grade Recombinant Human Noggin Fc Chimera (Catalog # 3344-GMP) inhibits BMP-4-induced alkaline phosphatase production in the ATDC5 mouse chondrogenic cell line. The ED50 for this effect is 0.1-0.4 µg/mL in the presence of 30 ng/mL of Recombinant Human BMP-4 (Catalog # 314-BP).
Recombinant Human Noggin Fc Chimera GMP Protein SDS-PAGE

Recombinant Human Noggin Fc Chimera GMP Protein SDS-PAGE

1 μg/lane of GMP-grade Recombinant Human Noggin Fc Chimera (Catalog # 3344-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing major bands at 60 kDa (R) and 120 kDa (NR).

Formulation, Preparation and Storage

3344-GMP
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: Noggin

Noggin is a secreted homodimeric glycoprotein that is an antagonist of bone morphogenetic proteins (BMPs) (1, 2). Human Noggin cDNA encodes a 232 amino acid (aa) precursor protein; cleavage of a 19 aa signal peptide generates the 213 aa mature protein which contains an N-terminal acidic region, a central basic heparin‑binding segment and a C-terminal cysteine-knot structure (2). Secreted Noggin probably remains close to the cell surface due to its binding of heparin‑containing proteoglycans (3). Noggin is very highly conserved among vertebrates, such that mature human Noggin shares 99%, 99%, 98%, 97% and 89% aa sequence identity with mouse, rat, bovine, equine and chicken Noggin, respectively. Noggin binds some BMPs such as BMP-4 with high affinity and others such as BMP-7 with lower affinity, antagonizing BMP bioactivities by blocking epitopes on BMPs that are needed for binding to both type I and type II receptors (2, 4). 

During embryogenesis, Noggin antagonizes specific BMPs at defined times during neural tube, somite and cardiomyocyte growth and patterning (5-7). During skeletal development, Noggin prevents chondrocyte hyperplasia, thus allowing proper formation of joints (4). Mutations within the cysteine-knot region of human Noggin are linked to multiple types of skeletal dysplasias that result in apical joint fusions (8). Noggin is expressed in defined areas of the adult central nervous system and peripheral tissues such as lung, skeletal muscle and skin (1). During culture of human embryonic stem cells (hESC) without feeder layers or conditioned medium, but with addition of FGF basic, addition of Noggin to antagonize BMP activity allows hESC to maintain their undifferentiated, pluripotent state (9, 10). In differentiation protocols, Noggin has been used to create neural crest stem cells from induced pluripotent stem cells (11). 

Because of its importance in the development of tissues, regenerative medicine utilizes Noggin to generate cells for intestinal tissues or organoids in vitro (12). Noggin is also an important factor for stimulating bone development and has neuroprotective effects in early stages of spinal cord injury (13, 14). Expression of Noggin can help contain or reduce metastatic lesions by limiting BMP signaling, making it a therapeutic option for cancer treatment (15). Noggin has been used to create bladder cancer organoids that can serve as a tissue model in preclinical testing of chimeric antigen receptor (CAR)-T-cell immunotherapy (16).

References

  1. Valenzuela, D.M. et al. (1995) J. Neurosci. 15:6077.
  2. Groppe, J. et al. (2002) Nature 420:636.
  3. Paine-Saunders, S et al. (2002) J. Biol. Chem. 277:2089.
  4. Brunet, L. J. et al. (1998) Science 280:1455.
  5. McMahon, J. A. et al. (1998) Genes Dev. 12:1438.
  6. Itsykson, P. et al. (2005) Mol. Cell. Neurosci. 30:24.
  7. Yuasa, S. et al. (2005) Nat. Biotechnol. 23:607.
  8. Gong, Y. et al. (1999) Nat. Genet. 21:302.
  9. Xu, R.-H. et al. (2005) Nat. Methods 2:185.
  10. Wang, G. et al. (2005) Biochem. Biophys. Res. Commun. 330:934.
  11. Abe, R. et al. (2021) J. Rural. Med. 16:143.
  12. Kim, S. et al. (2022) Nat. Commu. 13:1692.
  13. Malijauskaite, S. et al. (2021) Cytokines Growth Factor Rev. 60:76.
  14. Al-Sammarraie, N. et al. (2022) Neural Regen Res. 18:492.
  15. Davis, H. et al. (2016) Cytokines Growth Factor Rev. 27:81.
  16. Yu, L. et al. (2021) Clin. Transl. Immunology 10:e1248.

Alternate Names

NOG, SYM1, SYNS1, SYNS1A

Entrez Gene IDs

9241 (Human); 18121 (Mouse)

Gene Symbol

NOG

UniProt

Q13253.1

Additional Noggin Products

Product Documents for Recombinant Human Noggin Fc Chimera GMP Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Manufacturing Specifications

GMP Proteins
R&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.


R&D Systems' quality focus includes:

  • Manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
  • Documented processes and QA control of documentation and process changes
  • Personnel training programs
  • Raw material testing and vendor qualification/monitoring
  • Fully validated equipment, processes and test methods
  • Equipment calibration schedules using a computerized calibration program
  • Facility maintenance, safety programs and pest control
  • Material review process for variances
  • Monitoring of stability over product shelf-life


R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:

  • N-terminal amino acid analysis, SDS-PAGE analysis, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
  • Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial testing according to USP
  • Host Cell Protein testing performed by ELISA
  • Mycoplasma testing by ribosomal RNA hybridization assay


Additional testing and documentation requested by the customer can be arranged at an additional cost.

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.

R&D Systems sells GMP grade products for preclinical or clinical ex vivo use. They are not for in vivo use. Please read the following End User Terms prior to using this product.

Product Specific Notices for Recombinant Human Noggin Fc Chimera GMP Protein, CF

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

We suggest you print and retain a copy of these End User Terms of Use of Product for your records.

The End User is aware that R&D Systems, Inc. sells GMP products for preclinical or clinical ex vivo use and not for in vivo use. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.

You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.

 

TERMS AND CONDITIONS

The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.

R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.

For preclinical, or clinical ex vivo use

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.